Biotech Values

[10nisman]

I think your 20% is low, but 280m is ~5 bucks eps to the bottom line.

Using a 60M fully diluted share count, applying a 40% tax rate and the $280M turns into approximately $2.80 in additional annual bottom line free-cash flow/EPS per share. Clearly that is nothing to sneeze at especially when you consider mC could be generating similar to more in free-cash flow/EPS per share.

IMHO, the market and the sell-side analysts are a sleep at the wheel when considering MNTA's potential and likely will not awaken until mC is approved. I wonder if any analysts will up their views/target prices on MNTA now that an FoB partnership is inked and the risk of not signing an FoB deal has been removed.